AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a late-stage study
https://www.marketscreener.com/news/astrazeneca-s-rare-immune-disorder-drug-succeeds-in-advanced-trial-ce7c5cd3dc8bf42d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.